Boditech Med Inc. and SphingoTec GmbH announced they have entered into a market development agreement (MDA), building on their previous licensing collaboration for the kidney function biomarker penKid. The MDA solidifies the partnership between Boditech and SphingoTec, aiming to support the successful commercialization of the assay for the biomarker penKid on the AFIAS platforms. This strategic collaboration unites the expertise and resources of both companies to drive advancements in kidney health assessment, addressing the unmet needs in acute kidney injury (AKI) diagnosis. AKI is a life-threatening condition that affects 13 million patients worldwide, and existing diagnostic standards often fall short, particularly for non-stable patients.

The biomarker penKid shows significant potential to address these unmet needs as it delivers information on kidney function earlier and more precisely than the currently used markers, even under renal replacement therapy.